Novo Nordisk A/S Basic Information, Manufacturing Base, Sales Area, and Competitors
|
Sr. No. |
Item |
Description |
|
1 |
Company Name |
Novo Nordisk A/S |
|
2 |
Website |
www.novonordisk-us.com |
|
3 |
Established Date |
1923 |
|
4 |
Headquartered |
Denmark |
|
5 |
Market Position/ History |
Novo Nordisk A/S is a pharmaceutical company involved in the manufacturing of medicines or drugs for diabetes and obesity care, and Rare diseases. The company was established in 1923 and is headquartered in Denmark. In the 1930s, Novo and Nordisk each established diabetes hospitals in Denmark to provide specialized diabetes care. In 1951, Nordisk’s foundation was established in the 1920s and Novo followed. Thereafter in 1969s, Novo opened a production plant in Kalundborg, Denmark. Then in 1985, the comapny launched NovoPen, the first insulin pen device. In 2019, a major breakthrough that further expanded treatment options and reduced barriers, this innovative tablet eliminates the need for injections with GLP-1 – a welcome relief for many people living with type 2 diabetes. |
|
6 |
Sales Area |
Worldwide |
|
7 |
Manufacturing Location |
16 production sites in nine countries (Algeria, Brazil, China, Denmark, France, Iran, Japan, Russia and US). 10 research and development centres in five countries (China, Denmark, India, UK and US). |
|
8 |
No. of Employees |
~64,319 (as of December 2023) |
|
9 |
Competitors |
|
|
10 |
CEO |
Lars Fruergaard Jørgensen |
|
11 |
Ownership Type |
Public |
|
12 |
Contact Inform Novo Nordisk A/S is a pharmaceutical company involved in the manufacturing of medicines or drugs for diabetes and obesity care, and rare diseases. The company has a presence in over 170 countries. The company has 10 research and development centers in five countries (China, Denmark, India, the UK, and the US), and 16 production sites in nine countries (Algeria, Brazil, China, Denmark, France, Iran, Japan, Russia, and US). Novo Nordisk operates in two business segments based on therapies: Diabetes and Obesity care and Rare disease, representing the entirety of the Group's operations. ation |
Novo Alle 1 2880 Bagsværd Denmark Tel: +45-4444-8888 |
Business Segment/ Overview:
Novo Nordisk A/S is a pharmaceutical company involved in the manufacturing of medicines or drugs for diabetes and obesity care, and rare diseases. The company has a presence in over 170 countries. The company has 10 research and development centers in five countries (China, Denmark, India, the UK, and the US), and 16 production sites in nine countries (Algeria, Brazil, China, Denmark, France, Iran, Japan, Russia, and US).
Novo Nordisk operates in two business segments based on therapies: Diabetes and Obesity care and Rare disease, representing the entirety of the Group's operations.
Anti-Obesity Drugs Product Types Specification
|
Product |
Description |
|
Saxenda (liraglutide) injection 3 mg |
Saxenda and SaxendaCare are registered trademarks of Novo Nordisk A/S
|
|
Wegovy (semaglutide) injection 2.4 mg |
Wegovy Prescribing Information, including Boxed Warning Wegovy is a registered trademark of Novo Nordisk A/S.
|
Recent Developments:
|
Year |
Latest News |
|
February 2024 |
Novo Nordisk announced that the company has agreed to acquire three fill-finish sites from Novo Holdings A/S (Novo Holdings) in connection with a transaction where Novo Holdings has agreed to acquire Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in Somerset, New Jersey (US). Novo Nordisk and Catalent have a long-standing collaboration. |
|
August 2023 |
Novo Nordisk strikes $11bn deal to expand production of weight loss drug Novo Nordisk has agreed to acquire three manufacturing sites for $11bn, as the Danish drugmaker races to expand production of the weight loss drugs whose runaway success has sent the company’s valuation beyond $500bn. The group reported record sales for 2023, driven by surging demand for its diabetes and anti-obesity drugs Ozempic and Wegovy. However, Novo Nordisk warned that supply chain bottlenecks were hampering its ability to produce enough of the best-selling treatments. |
Author's Detail:
Nisha Deore /
LinkedIn
Nisha Deore is a highly skilled Research Analyst with over three years of experience specializing in the agriculture and food & beverage sectors. Her expertise encompasses secondary research, data mining, competitive analysis, and the development of detailed collateral and PR materials. Known for her meticulous approach, Nisha designs robust research methodologies and delivers actionable insights that support her organization’s commercial and financial objectives.
In her current role, Nisha manages research for both the agriculture and food & beverage categories, leading initiatives to uncover market opportunities and enhance competitive positioning. Her strong analytical skills and ability to provide clear, impactful findings have been crucial to her team’s success. With a deep passion for both sectors and a commitment to continuous professional development, Nisha remains an invaluable asset in the dynamic landscape of market research.